Αρχική World News Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients... World News Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin Από Ogkologos - 23 Φεβρουαρίου, 2026 420 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Do Cancer Survivors Have To Be Positive All the Time? Letting... 10 Νοεμβρίου, 2021 More Immunotherapy Options Approved for Treating Endometrial Cancer 6 Αυγούστου, 2024 “Your Stories” Podcast: Amplifying Patient Voices 8 Σεπτεμβρίου, 2020 FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... 25 Φεβρουαρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ Can Cooking With Nonstick Cookware Increase Your Cancer Risk? EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib ¿Ahora qué? 10 maneras de adaptarse a la vida cotidiana después...